| Trademark Snap Shot Publication Stylesheet (Table presents the data on Publication Approval) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 88108634 | FILING DATE | 09/07/2018 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | STIGLITZ, SUSAN R |
L.O. ASSIGNED | 109 |
PUB INFORMATION |
|||
| RUN DATE | 10/14/2020 | ||
| PUB DATE | 02/25/2020 | ||
| STATUS | 819-SU - REGISTRATION REVIEW COMPLETE | ||
| STATUS DATE | 10/13/2020 | ||
| LITERAL MARK ELEMENT | IMMUNOTAC | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | YES | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | NO | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | YES |
| LITERAL MARK ELEMENT | IMMUNOTAC |
| MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 20-OWNER AT PUBLICATION |
| NAME | Silverback Therapeutics, Inc. |
| ADDRESS | 500 Fairview Avenue North, Suite 600 Seattle, WA 98109 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Systemically delivered, locally active immune modulatory conjugates in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceuticals and pharmaceutical preparations of systemically delivered, locally active immune modulatory conjugates for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; engineered immunomodulatory therapeutics in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | 06/26/2020 | FIRST USE IN COMMERCE DATE | 06/26/2020 | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 10/14/2020 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 028 |
| 10/13/2020 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 027 |
| 09/22/2020 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | 026 |
| 09/08/2020 | IUAF | S | USE AMENDMENT FILED | 025 |
| 09/22/2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | 024 |
| 09/08/2020 | EISU | I | TEAS STATEMENT OF USE RECEIVED | 023 |
| 04/21/2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 022 |
| 02/25/2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 021 |
| 02/25/2020 | PUBO | A | PUBLISHED FOR OPPOSITION | 020 |
| 02/05/2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 019 |
| 01/21/2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 018 |
| 01/09/2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 017 |
| 01/08/2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 016 |
| 01/08/2020 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | 015 |
| 07/08/2019 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | 014 |
| 07/08/2019 | GNFR | O | FINAL REFUSAL E-MAILED | 013 |
| 07/08/2019 | CNFR | R | FINAL REFUSAL WRITTEN | 012 |
| 06/19/2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 011 |
| 06/18/2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 010 |
| 06/18/2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 009 |
| 12/31/2018 | LOPR | P | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | 008 |
| 12/28/2018 | LOPT | I | LETTER OF PROTEST ACCEPTED | 007 |
| 12/19/2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 006 |
| 12/19/2018 | GNRT | F | NON-FINAL ACTION E-MAILED | 005 |
| 12/19/2018 | CNRT | R | NON-FINAL ACTION WRITTEN | 004 |
| 12/18/2018 | DOCK | D | ASSIGNED TO EXAMINER | 003 |
| 09/15/2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
| 09/11/2018 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Joi A. White |
| CORRESPONDENCE ADDRESS | Joi A. White Carr & Ferrell LLP 120 Constitution Drive Menlo Park, CA 94025 |
| DOMESTIC REPRESENTATIVE | NONE |
PRIOR OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Silverback Therapeutics, Inc. |
| ADDRESS | 500 Fairview Avenue North, Suite 600 Seattle, WA 98109 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |